Clinical Trials Directory

Trials / Completed

CompletedNCT00280436

Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia

A Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Effects of GW679769 on Polysomnographic Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Elderly and Non-elderly Subjects With Primary Insomnia

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
122 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is designed to find the optimal (best) doses of GW679769 that promote sleep onset and maintain sleep during two consecutive nights of dosing without significant next-day thinking impairment and drowsiness in subjects with primary insomnia.

Conditions

Interventions

TypeNameDescription
DRUGGW679769

Timeline

Start date
2006-01-01
Primary completion
2007-03-01
Completion
2007-03-01
First posted
2006-01-23
Last updated
2015-04-16

Locations

26 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00280436. Inclusion in this directory is not an endorsement.